At a glance
ClinicalIndex Comparison RecordN/ACompleted· 89 enrolled
Drug / intervention
Trelagliptindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Specified Drug Use Surveillance on Zafatek Tablets 25 mg -Surveillance on Long-Term Use of Trelagliptin Tablets in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-Stage Renal Failure-
In Brief
An observational study evaluating Trelagliptin for Type 2 Diabetes Mellitus. Completed, enrolled 89 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of trelagliptin tablets in patients with type 2 diabetes mellitus complicated by severe renal impairment or end-stage renal failure in the routine clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartMar 2020
Primary CompletionJan 2023
TodayJul 2026
First PostedFeb 26, 2020
Enrollment StartMar 1, 2020
Primary CompletionJan 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 6.4 years ago
Interventions
Trelagliptindrug
Trelagliptin tablets